The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Subscribe To Our Newsletter & Stay Updated
